Outcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkey

Basit Öğe Kaydı
dc.authorid0000-0001-6690-721Xen_US
dc.authorid0000-0003-3435-757Xen_US
dc.authorid0000-0001-7410-4310en_US
dc.authorid0000-0002-1895-7359en_US
dc.authorid0000-0002-8552-4596en_US
dc.authorid0000-0001-8463-2723en_US
dc.contributor.authorYozgat, Ayça Koca
dc.contributor.authorLeblebisatan, Göksel
dc.contributor.authorAkbayram, Sinan
dc.contributor.authorÖzel, Simge Çınar
dc.contributor.authorKarakaş, Zeynep
dc.contributor.authorErduran, Erol
dc.contributor.authorSöker, Murat
dc.date.accessioned2024-03-20T11:41:38Z
dc.date.available2024-03-20T11:41:38Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractObjective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5±4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of ≥50x109/L was 11.6±8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8±9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.en_US
dc.identifier.citationYozgat, A. K., Leblebisatan, G., Akbayram, S., Özel, S. Ç., Karakaş, Z., Erduran, E. ve diğerleri. (2020). Outcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkey. Turkish Journal of Hematology, 37(3), 139-144.en_US
dc.identifier.doi10.4274/tjh.galenos.2020.2019.0380en_US
dc.identifier.endpage144en_US
dc.identifier.issn1300-7777
dc.identifier.issue3en_US
dc.identifier.pmid32181630en_US
dc.identifier.scopus2-s2.0-85090080214en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage139en_US
dc.identifier.trdizinid380843en_US
dc.identifier.urihttps://jag.journalagent.com/tjh/pdfs/TJH_37_3_139_144.pdf
dc.identifier.urihttps://hdl.handle.net/11468/13658
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/380843
dc.identifier.volume37en_US
dc.identifier.wosWOS:000564138800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorSöker, Murat
dc.language.isoenen_US
dc.publisherTurkish Society of Hematologyen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEltrombopagen_US
dc.subjectImmune thrombocytopeniaen_US
dc.subjectIron deficiencyen_US
dc.titleOutcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkeyen_US
dc.title.alternativeİmmün trombositopenili çocuk hastalarda eltrombopag tedavisi ve tedaviye bağlı demir eksikliğien_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Outcomes of Eltrombopag Treatment and Development of Iron.pdf
Boyut:
226.98 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu